Magi Farre

List of Publications by Year in Descending Order

Source: https://exaly.com/author-pdf/1599587/magi-farre-publications-by-year.pdf

Version: 2024-04-10

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

6,577 184 44 74 h-index g-index citations papers 5.56 7,597 194 4.9 avg, IF L-index ext. citations ext. papers

#	Paper	IF	Citations
184	Nocebo Response in Attention Deficit Hyperactivity Disorder: Meta-Analysis and Meta-Regression of 105 Randomized Clinical Trials <i>Journal of Attention Disorders</i> , 2022 , 10870547221075845	3.7	
183	High-titre methylene blue-treated convalescent plasma as an early treatment for outpatients with COVID-19: a randomised, placebo-controlled trial <i>Lancet Respiratory Medicine,the</i> , 2022 ,	35.1	6
182	Drug and MDMA Interactions Implications for Public Health 2022 , 1-26		
181	Abuse Potential of Cathinones in Humans: A Systematic Review <i>Journal of Clinical Medicine</i> , 2022 , 11,	5.1	2
180	BDNF and Cortisol in the Diagnosis of Cocaine-Induced Depression <i>Frontiers in Psychiatry</i> , 2022 , 13, 836771	5	
179	New Synthetic Opioids Use among Patients in Treatment for an Opioid Use Disorder in Barcelona <i>European Addiction Research</i> , 2022 , 1-8	4.6	1
178	Vascular Endothelial Growth Factor as a Potential Biomarker of Neuroinflammation and Frontal Cognitive Impairment in Patients with Alcohol Use Disorder. <i>Biomedicines</i> , 2022 , 10, 947	4.8	О
177	New Psychoactive Substances Consumption in Opioid-Use Disorder Patients. <i>Biology</i> , 2022 , 11, 645	4.9	O
176	Addiction of Hallucinogens, Dissociatives, Designer Drugs and Elegal HighsElUpdate on Potential Therapeutic Use 2021 , 259-279		1
175	Acute Pharmacological Effects and Oral Fluid Biomarkers of the Synthetic Cannabinoid UR-144 and THC in Recreational Users. <i>Biology</i> , 2021 , 10,	4.9	4
174	Ultra-High Performance Liquid Chromatography-High Resolution Mass Spectrometry and High-Sensitivity Gas Chromatography-Mass Spectrometry Screening of Classic Drugs and New Psychoactive Substances and Metabolites in Urine of Consumers. <i>International Journal of Molecular</i>	6.3	7
173	Daidzein modulates cocaine-reinforcing effects and cue-induced cocaine reinstatement in CD-1 male mice. <i>Psychopharmacology</i> , 2021 , 238, 1923-1936	4.7	0
172	Analysis of the Adherence and Safety of Second Oral Glucose-Lowering Therapy in Routine Practice From the Mediterranean Area: A Retrospective Cohort Study. <i>Frontiers in Endocrinology</i> , 2021 , 12, 7083	7 5 :7	2
171	Disposition of cannabinoids and their metabolites in serum, oral fluid, sweat patch and urine from healthy individuals treated with pharmaceutical preparations of medical cannabis. <i>Phytotherapy Research</i> , 2021 , 35, 1646-1657	6.7	5
170	UHPLC-MS/MS analysis of cannabidiol metabolites in serum and urine samples. Application to an individual treated with medical cannabis. <i>Talanta</i> , 2021 , 223, 121772	6.2	10
169	A Cluster-Randomized Trial of Hydroxychloroquine for Prevention of Covid-19. <i>New England Journal of Medicine</i> , 2021 , 384, 417-427	59.2	108
168	Analysis of the effectiveness of second oral glucose-lowering therapy in routine clinical practice from the mediterranean area: A retrospective cohort study. <i>Diabetes Research and Clinical Practice</i> , 2021 , 171, 108616	7.4	1

(2020-2021)

167	Acute Pharmacological Effects of Oral and Intranasal Mephedrone: An Observational Study in Humans. <i>Pharmaceuticals</i> , 2021 , 14,	5.2	5
166	Long-Term Outcomes of Patients With Cocaine Use Disorder: A 18-years Addiction Cohort Study. <i>Frontiers in Pharmacology</i> , 2021 , 12, 625610	5.6	1
165	Acute Pharmacological Effects and Oral Fluid Concentrations of the Synthetic Cannabinoids JWH-122 and JWH-210 in Humans After Self-Administration: An Observational Study. <i>Frontiers in Pharmacology</i> , 2021 , 12, 705643	5.6	O
164	A Comparison of Acute Pharmacological Effects of Methylone and MDMA Administration in Humans and Oral Fluid Concentrations as Biomarkers of Exposure. <i>Biology</i> , 2021 , 10,	4.9	3
163	Drug-Related Deaths in a Tertiary Hospital: Characteristics of Spontaneously Reported Cases and Comparison to Cases Detected from a Retrospective Study. <i>Journal of Clinical Medicine</i> , 2021 , 10,	5.1	1
162	Interaction of Energy Drinks with Prescription Medication and Drugs of Abuse. <i>Pharmaceutics</i> , 2021 , 13,	6.4	3
161	Disposition of Phytocannabinoids, Their Acidic Precursors and Their Metabolites in Biological Matrices of Healthy Individuals Treated with Vaporized Medical Cannabis. <i>Pharmaceuticals</i> , 2021 , 14,	5.2	6
160	Acute Effects of 2C-E in Humans: An Observational Study. Frontiers in Pharmacology, 2020 , 11, 233	5.6	7
159	MDMA interactions with pharmaceuticals and drugs of abuse. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2020 , 16, 357-369	5.5	10
158	Oral Administration of Cannabis and 🗗 tetrahydrocannabinol (THC) Preparations: A Systematic Review. <i>Medicina (Lithuania)</i> , 2020 , 56,	3.1	16
157	Quality of Life, Mental Health, Personality and Patterns of Use in Self-Medicated Cannabis Users with Chronic Diseases: A 12-Month Longitudinal Study. <i>Phytotherapy Research</i> , 2020 , 34, 1670-1677	6.7	8
156	LC-MS/MS method for the quantification of new psychoactive substances and evaluation of their urinary detection in humans for doping control analysis. <i>Drug Testing and Analysis</i> , 2020 , 12, 785-797	3.5	9
155	Effects of cannabis exposure in the prenatal and adolescent periods: Preclinical and clinical studies in both sexes. <i>Frontiers in Neuroendocrinology</i> , 2020 , 57, 100841	8.9	9
154	Fast and sensitive UHPLC-MS/MS analysis of cannabinoids and their acid precursors in pharmaceutical preparations of medical cannabis and their metabolites in conventional and non-conventional biological matrices of treated individual. <i>Talanta</i> , 2020 , 209, 120537	6.2	22
153	UHPLC-HRMS and GC-MS Screening of a Selection of Synthetic Cannabinoids and Metabolites in Urine of Consumers. <i>Medicina (Lithuania)</i> , 2020 , 56,	3.1	8
152	Disposition of Cannabidiol Metabolites in Serum and Urine from Healthy Individuals Treated with Pharmaceutical Preparations of Medical Cannabis. <i>Pharmaceuticals</i> , 2020 , 13,	5.2	3
151	Determination of the Synthetic Cannabinoids JWH-122, JWH-210, UR-144 in Oral Fluid of Consumers by GC-MS and Quantification of Parent Compounds and Metabolites by UHPLC-MS/MS. <i>International Journal of Molecular Sciences</i> , 2020 , 21,	6.3	4
150	The Tryptophan System in Cocaine-Induced Depression. <i>Journal of Clinical Medicine</i> , 2020 , 9,	5.1	4

149	A phase 1, randomized double-blind, placebo controlled trial to evaluate safety and efficacy of epigallocatechin-3-gallate and cognitive training in adults with Fragile X syndrome. <i>Clinical Nutrition</i> , 2020 , 39, 378-387	5.9	9
148	Soy Isoflavone Extract Does Not Increase the Intoxicating Effects of Acute Alcohol Ingestion in Human Volunteers. <i>Frontiers in Pharmacology</i> , 2019 , 10, 131	5.6	3
147	Meconium Biomarkers of Prenatal Alcohol Exposure 2019 , 585-594		
146	Inflammatory mediators and dual depression: Potential biomarkers in plasma of primary and substance-induced major depression in cocaine and alcohol use disorders. <i>PLoS ONE</i> , 2019 , 14, e021379	3 ·7	13
145	Psychopathological symptoms associated with synthetic cannabinoid use: a comparison with natural cannabis. <i>Psychopharmacology</i> , 2019 , 236, 2677-2685	4.7	17
144	Reply. <i>Medicina Cl</i> ū ica, 2019 , 152, 79-80	1	
143	Dose-Response Pharmacological Study of Mephedrone and Its Metabolites: Pharmacokinetics, Serotoninergic Effects, and Impact of CYP2D6 Genetic Variation. <i>Clinical Pharmacology and Therapeutics</i> , 2019 , 106, 596-604	6.1	12
142	Mephedrone and Alcohol Interactions in Humans. Frontiers in Pharmacology, 2019, 10, 1588	5.6	14
141	Dietary inflammatory index and all-cause mortality in large cohorts: The SUN and PREDIMED studies. <i>Clinical Nutrition</i> , 2019 , 38, 1221-1231	5.9	55
140	Therapeutic Use of LSD in Psychiatry: A Systematic Review of Randomized-Controlled Clinical Trials. <i>Frontiers in Psychiatry</i> , 2019 , 10, 943	5	32
139	Short- and medium-term impact of bariatric surgery on the activities of CYP2D6, CYP3A4, CYP2C9, and CYP1A2 in morbid obesity. <i>Scientific Reports</i> , 2019 , 9, 20405	4.9	10
138	Metabolomics predicts the pharmacological profile of new psychoactive substances. <i>Journal of Psychopharmacology</i> , 2019 , 33, 347-354	4.6	16
137	Potential Use of Ayahuasca in Grief Therapy. Omega: Journal of Death and Dying, 2019, 79, 260-285	1.6	12
136	Ethics in clinical research: Contributions of the new version of the Council for International Organizations of Medical Sciences guidelines. <i>Medicina Claica (English Edition)</i> , 2018 , 150, 282-285	0.3	O
135	Depressive mood ratings are reduced by MDMA in female polydrug ecstasy users homozygous for the l-allele of the serotonin transporter. <i>Scientific Reports</i> , 2018 , 8, 1061	4.9	7
134	Key interindividual determinants in MDMA pharmacodynamics. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2018 , 14, 183-195	5.5	11
133	Ethics in clinical research: Contributions of the new version of the Council for International Organizations of Medical Sciences guidelines. <i>Medicina Claica</i> , 2018 , 150, 282-285	1	3
132	Acute Pharmacological Effects of 2C-B in Humans: An Observational Study. <i>Frontiers in Pharmacology</i> , 2018 , 9, 206	5.6	27

131	Cannabinoids: from pot to lab. International Journal of Medical Sciences, 2018, 15, 1286-1295	3.7	34	
130	Patients with alcohol use disorder: initial results from a prospective multicenter registry in the Spanish Network on Addiction Disorders. CohRTA Study. <i>Revista De Psicologia De La Salud</i> , 2018 , 30, 29	2 ¹ 300	1	
129	The efficacy of computerized interventions to reduce cannabis use: A systematic review and meta-analysis. <i>Addictive Behaviors</i> , 2018 , 79, 52-60	4.2	24	
128	Peripheral endocannabinoid concentrations are not associated with verbal memory impairment during MDMA intoxication. <i>Psychopharmacology</i> , 2018 , 235, 709-717	4.7	2	
127	Drug-related deaths in hospital inpatients: A retrospective cohort study. <i>British Journal of Clinical Pharmacology</i> , 2018 , 84, 542-552	3.8	32	
126	Drug Interactions With New Synthetic Opioids. <i>Frontiers in Pharmacology</i> , 2018 , 9, 1145	5.6	27	
125	Assessment of Efficacy and Tolerability of Medicinal Cannabinoids in Patients With Multiple Sclerosis: A Systematic Review and Meta-analysis. <i>JAMA Network Open</i> , 2018 , 1, e183485	10.4	34	
124	Do serum markers of liver fibrosis vary by HCV infection in patients with alcohol use disorder?. <i>Drug and Alcohol Dependence</i> , 2018 , 188, 180-186	4.9	3	
123	Effect of olive oil phenolic compounds on the expression of blood pressure-related genes in healthy individuals. <i>European Journal of Nutrition</i> , 2017 , 56, 663-670	5.2	35	
122	Effect of virgin olive oil and thyme phenolic compounds on blood lipid profile: implications of human gut microbiota. <i>European Journal of Nutrition</i> , 2017 , 56, 119-131		70	
121	Attenuated frontal and sensory inputs to the basal ganglia in cannabis users. <i>Addiction Biology</i> , 2017 , 22, 1036-1047	4.6	29	
120	Pharmacokinetics in Morbid Obesity: Influence of Two Bariatric Surgery Techniques on Paracetamol and Caffeine Metabolism. <i>Obesity Surgery</i> , 2017 , 27, 3194-3201	3.7	17	
119	Something New about Something Old: A 10-Year Follow-Up on Classical and New Psychoactive Tryptamines and Results of Analysis. <i>Journal of Psychoactive Drugs</i> , 2017 , 49, 297-305	3.6	51	
118	GC-MS Quantification Method for Mephedrone in Plasma and Urine: Application to Human Pharmacokinetics. <i>Journal of Analytical Toxicology</i> , 2017 , 41, 100-106	2.9	17	
117	Answer to the Letter to the Editor Concerning "Pharmacokinetics in Morbid Obesity: Influence of Two Bariatric Surgery Techniques on Paracetamol and Caffeine Metabolism". <i>Obesity Surgery</i> , 2017 , 27, 3006-3007	3.7		
116	Pharmacokinetics of Mephedrone and Its Metabolites in Human by LC-MS/MS. AAPS Journal, 2017,	3.7	23	
110	19, 1767-1778	<i>J</i> •7		
115	19, 1767-1778 Cannabis as Secondary Drug Is Not Associated With a Greater Risk of Death in Patients With Opiate, Cocaine, or Alcohol Dependence. <i>Journal of Addiction Medicine</i> , 2017 , 11, 34-39	3.8	4	

113	Non-Linear Formation of EtG and FAEEs after Controlled Administration of Low to Moderate Doses of Ethanol. <i>Alcohol and Alcoholism</i> , 2017 , 52, 587-594	3.5	5
112	Corrigendum to "Genetic and protein biomarkers in blood for the improved detection of GH abuse" [J. Pharm. Biomed. Anal. 128 (2016) 111-118, doi: 10.1016/j.jpba.2016.05.022.]. <i>Journal of Pharmaceutical and Biomedical Analysis</i> , 2017 , 134, 385	3.5	
111	Evaluation of fibronectin 1 in one dried blood spot and in urine after rhGH treatment. <i>Drug Testing and Analysis</i> , 2017 , 9, 1011-1016	3.5	12
110	The hidden web and the fentanyl problem: Detection of ocfentanil as an adulterant in heroin. <i>International Journal of Drug Policy</i> , 2017 , 40, 78-83	5.5	51
109	Monitoring nicotine intake from e-cigarettes: measurement of parent drug and metabolites in oral fluid and plasma. <i>Clinical Chemistry and Laboratory Medicine</i> , 2017 , 55, 415-423	5.9	13
108	A Biomarker to Differentiate between Primary and Cocaine-Induced Major Depression in Cocaine Use Disorder: The Role of Platelet IRAS/Nischarin (I-Imidazoline Receptor). <i>Frontiers in Psychiatry</i> , 2017 , 8, 258	5	4
107	Mephedrone Concentrations in Cases of Clinical Intoxication. <i>Current Pharmaceutical Design</i> , 2017 , 23, 5511-5522	3.3	59
106	Neuropsychiatric and General Interactions of Natural and Synthetic Cannabinoids with Drugs of Abuse and Medicines. <i>CNS and Neurological Disorders - Drug Targets</i> , 2017 , 16, 554-566	2.6	23
105	Concurrent Use of Cannabis and Alcohol: Neuropsychiatric Effect Consequences. <i>CNS and Neurological Disorders - Drug Targets</i> , 2017 , 16, 592-597	2.6	6
104	Clinical Pharmacology of the Synthetic Cathinone Mephedrone. <i>Current Topics in Behavioral Neurosciences</i> , 2017 , 32, 313-331	3.4	17
103	Neurocognitive performance following acute mephedrone administration, with and without alcohol. <i>Journal of Psychopharmacology</i> , 2016 , 30, 1305-1312	4.6	20
102	Safety and efficacy of cognitive training plus epigallocatechin-3-gallate in young adults with Down's syndrome (TESDAD): a double-blind, randomised, placebo-controlled, phase 2 trial. <i>Lancet Neurology, The</i> , 2016 , 15, 801-810	24.1	152
101	Elakkalan Emerging Trend Or a Mass Media Phenomenon? Presence of alpha-pvp in Samples Submitted To a Drug Checking Facility. <i>European Psychiatry</i> , 2016 , 33, S442-S442	6	1
100	Analysis of free hydroxytyrosol in human plasma following the administration of olive oil. <i>Journal of Chromatography A</i> , 2016 , 1437, 183-190	4.5	35
99	Bilastine: a new antihistamine with an optimal benefit-to-risk ratio for safety during driving. <i>Expert Opinion on Drug Safety</i> , 2016 , 15, 89-98	4.1	22
98	Facial emotion processing in patients with social anxiety disorder and Williams-Beuren syndrome: an fMRI study. <i>Journal of Psychiatry and Neuroscience</i> , 2016 , 41, 182-91	4.5	11
97	Alcohol Consumption during Pregnancy: Analysis of Two Direct Metabolites of Ethanol in Meconium. <i>International Journal of Molecular Sciences</i> , 2016 , 17, 417	6.3	4
96	PCP analogues in samples of Barcelona from 2009 to 2015. <i>European Psychiatry</i> , 2016 , 33, S117-S117	6	1

(2015-2016)

95	Genetic and protein biomarkers in blood for the improved detection of GH abuse. <i>Journal of Pharmaceutical and Biomedical Analysis</i> , 2016 , 128, 111-118	3.5	12
94	Metabolic disposition and biological significance of simple phenols of dietary origin: hydroxytyrosol and tyrosol. <i>Drug Metabolism Reviews</i> , 2016 , 48, 218-36	7	90
93	The synthetic cannabinoids: JWH, four years of analysis. <i>European Psychiatry</i> , 2016 , 33, S115-S116	6	2
92	Human Pharmacology of Mephedrone in Comparison with MDMA. <i>Neuropsychopharmacology</i> , 2016 , 41, 2704-13	8.7	108
91	Determination of Recent Growth Hormone Abuse Using a Single Dried Blood Spot. <i>Clinical Chemistry</i> , 2016 , 62, 1353-60	5.5	18
90	Moderate consumption of wine, through both its phenolic compounds and alcohol content, promotes hydroxytyrosol endogenous generation in humans. A randomized controlled trial. <i>Molecular Nutrition and Food Research</i> , 2015 , 59, 1213-6	5.9	27
89	Conditioned Subjective Responses to Socially Relevant Stimuli in Social Anxiety Disorder and Subclinical Social Anxiety. <i>Clinical Psychology and Psychotherapy</i> , 2015 , 22, 221-31	2.9	11
88	Olive Oil Polyphenols Decrease LDL Concentrations and LDL Atherogenicity in Men in a Randomized Controlled Trial. <i>Journal of Nutrition</i> , 2015 , 145, 1692-7	4.1	58
87	Pharmacokinetic Comparison of Soy Isoflavone Extracts in Human Plasma. <i>Journal of Agricultural and Food Chemistry</i> , 2015 , 63, 6946-53	5.7	21
86	Untargeted metabolomics in doping control: detection of new markers of testosterone misuse by ultrahigh performance liquid chromatography coupled to high-resolution mass spectrometry. <i>Analytical Chemistry</i> , 2015 , 87, 8373-80	7.8	34
85	Fit-for-Purpose Radio Receptor Assay for the Determination of Growth Hormone Secretagogues in Urine. <i>Journal of Biomolecular Screening</i> , 2015 , 20, 1268-76		5
84	Ethanol induces hydroxytyrosol formation in humans. <i>Pharmacological Research</i> , 2015 , 95-96, 27-33	10.2	16
83	Conditioned Fear Acquisition and Generalization in Generalized Anxiety Disorder. <i>Behavior Therapy</i> , 2015 , 46, 627-39	4.8	44
82	Potential role of olive oil phenolic compounds in the prevention of neurodegenerative diseases. <i>Molecules</i> , 2015 , 20, 4655-80	4.8	143
81	Changes in serotonin transporter (5-HTT) gene expression in peripheral blood cells after MDMA intake. <i>Psychopharmacology</i> , 2015 , 232, 1921-9	4.7	9
80	Anomalous brain functional connectivity contributing to poor adaptive behavior in Down syndrome. <i>Cortex</i> , 2015 , 64, 148-56	3.8	45
79	Complementary phenol-enriched olive oil improves HDL characteristics in hypercholesterolemic subjects. A randomized, double-blind, crossover, controlled trial. The VOHF study. <i>Molecular Nutrition and Food Research</i> , 2015 , 59, 1758-70	5.9	35
78	Semantic Verbal Fluency Pattern, Dementia Rating Scores and Adaptive Behavior Correlate With Plasma AB2 Concentrations in Down Syndrome Young Adults. <i>Frontiers in Behavioral Neuroscience</i> , 2015 , 9, 301	3.5	17

77	Salivary Secretory Disorders, Inducing Drugs, and Clinical Management. <i>International Journal of Medical Sciences</i> , 2015 , 12, 811-24	3.7	75
76	A new cognitive evaluation battery for Down syndrome and its relevance for clinical trials. <i>Frontiers in Psychology</i> , 2015 , 6, 708	3.4	44
75	Acute Effects of the Novel Psychoactive Drug 2C-B on Emotions. <i>BioMed Research International</i> , 2015 , 2015, 643878	3	20
74	In vitro study of the apical microleakage with resilon root canal filling using different final endodontic irrigants. <i>Journal of Clinical and Experimental Dentistry</i> , 2015 , 7, e212-7	1.4	5
73	Human pharmacology of 3,4-methylenedioxymethamphetamine (MDMA, ecstasy) after repeated doses taken 4 h apart Human pharmacology of MDMA after repeated doses taken 4 h apart. European Neuropsychopharmacology, 2015 , 25, 1637-49	1.2	19
72	Mass spectrometric evaluation of mephedrone in vivo human metabolism: identification of phase I and phase II metabolites, including a novel succinyl conjugate. <i>Drug Metabolism and Disposition</i> , 2015 , 43, 248-57	4	59
71	Detection and characterization of betamethasone metabolites in human urine by LC-MS/MS. <i>Drug Testing and Analysis</i> , 2015 , 7, 663-72	3.5	18
70	Addiction to Hallucinogens, Dissociatives, Designer Drugs and 🛭 egal Highs 2015 , 567-596		2
69	Functional connectivity alterations in brain networks relevant to self-awareness in chronic cannabis users. <i>Journal of Psychiatric Research</i> , 2014 , 51, 68-78	5.2	74
68	Functional effects of chronic paroxetine versus placebo on the fear, stress and anxiety brain circuit in Social Anxiety Disorder: initial validation of an imaging protocol for drug discovery. <i>European Neuropsychopharmacology</i> , 2014 , 24, 105-16	1.2	17
67	Determination of free serotonin and its metabolite 5-HIAA in blood human samples with consideration to pre-analytical factors. <i>Biomedical Chromatography</i> , 2014 , 28, 1641-6	1.7	9
66	Memory and mood during MDMA intoxication, with and without memantine pretreatment. <i>Neuropharmacology</i> , 2014 , 87, 198-205	5.5	23
65	The efficacy of cognitive behavioural therapy and advocacy interventions for women who have experienced intimate partner violence: a systematic review and meta-analysis. <i>Annals of Medicine</i> , 2014 , 46, 567-86	1.5	39
64	Common and distinct neural correlates of facial emotion processing in social anxiety disorder and Williams syndrome: A systematic review and voxel-based meta-analysis of functional resonance imaging studies. <i>Neuropsychologia</i> , 2014 , 64, 205-17	3.2	32
63	Metabolite profiling of olive oil and thyme phenols after a sustained intake of two phenol-enriched olive oils by humans: Identification of compliance markers. <i>Food Research International</i> , 2014 , 65, 59-68	7	40
62	ALDH5A1 variability in opioid dependent patients could influence response to methadone treatment. <i>European Neuropsychopharmacology</i> , 2014 , 24, 420-4	1.2	8
61	No evidence that MDMA-induced enhancement of emotional empathy is related to peripheral oxytocin levels or 5-HT1a receptor activation. <i>PLoS ONE</i> , 2014 , 9, e100719	3.7	57
60	The definition of placebo in the informed consent forms of clinical trials. <i>PLoS ONE</i> , 2014 , 9, e113654	3.7	10

(2012-2014)

59	Bilastine vs. hydroxyzine: occupation of brain histamine H1 -receptors evaluated by positron emission tomography in healthy volunteers. <i>British Journal of Clinical Pharmacology</i> , 2014 , 78, 970-80	3.8	42
58	Analysis of ECs and related compounds in plasma: artifactual isomerization and ex vivo enzymatic generation of 2-MGs. <i>Journal of Lipid Research</i> , 2014 , 55, 966-77	6.3	35
57	Modulation of brain structure by catechol-O-methyltransferase Val(158) Met polymorphism in chronic cannabis users. <i>Addiction Biology</i> , 2014 , 19, 722-32	4.6	29
56	Detection and characterization of triamcinolone acetonide metabolites in human urine by liquid chromatography/tandem mass spectrometry after intramuscular administration. <i>Rapid Communications in Mass Spectrometry</i> , 2014 , 28, 1829-39	2.2	16
55	Emerging drugs in Europe. Current Opinion in Psychiatry, 2014, 27, 243-50	4.9	44
54	Functional alteration in frontolimbic systems relevant to moral judgment in cocaine-dependent subjects. <i>Addiction Biology</i> , 2014 , 19, 272-81	4.6	37
53	Epigallocatechin-3-gallate, a DYRK1A inhibitor, rescues cognitive deficits in Down syndrome mouse models and in humans. <i>Molecular Nutrition and Food Research</i> , 2014 , 58, 278-88	5.9	182
52	3,4-methylenedioxymethamphetamine induces gene expression changes in rats related to serotonergic and dopaminergic systems, but not to neurotoxicity. <i>Neurotoxicity Research</i> , 2014 , 25, 161	- 4 ∙3	11
51	Cytokine-induced depression: current status and novel targets for depression therapy. <i>CNS and Neurological Disorders - Drug Targets</i> , 2014 , 13, 1066-74	2.6	27
50	Prophylactic antidepressant treatment of interferon-induced depression in chronic hepatitis C: a systematic review and meta-analysis. <i>Journal of Clinical Psychiatry</i> , 2014 , 75, e1113-21	4.6	30
49	Consumption of new psychoactive substances in a Spanish sample of research chemical users. <i>Human Psychopharmacology</i> , 2013 , 28, 332-40	2.3	30
48	Efficacy of psychostimulant drugs for amphetamine abuse or dependence. <i>The Cochrane Library</i> , 2013 , CD009695	5.2	36
47	Dose-dependent metabolic disposition of hydroxytyrosol and formation of mercapturates in rats. <i>Pharmacological Research</i> , 2013 , 77, 47-56	10.2	46
46	Urinary profile of methylprednisolone and its metabolites after oral and topical administrations. <i>Journal of Steroid Biochemistry and Molecular Biology</i> , 2013 , 138, 214-21	5.1	25
45	Human pharmacology of 3,4-methylenedioxymethamphetamine (MDMA, ecstasy) after repeated doses taken 2 h apart. <i>Psychopharmacology</i> , 2013 , 225, 883-93	4.7	30
44	Inhibition of MDMA-induced increase in cortisol does not prevent acute impairment of verbal memory. <i>British Journal of Pharmacology</i> , 2013 , 168, 607-17	8.6	15
43	Bioethical principles, clinical research and popular movies. <i>Medical Education</i> , 2013 , 47, 1141-2	3.7	4
42	MDMA, methamphetamine, and CYP2D6 pharmacogenetics: what is clinically relevant?. <i>Frontiers in Genetics</i> , 2012 , 3, 235	4.5	52

41	Clinical pharmacology of 3,4-methylenedioxymethamphetamine (MDMA, "ecstasy"): the influence of gender and genetics (CYP2D6, COMT, 5-HTT). <i>PLoS ONE</i> , 2012 , 7, e47599	3.7	40
40	Identifying emerging trends in recreational drug use; outcomes from the Psychonaut Web Mapping Project. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , 2012 , 39, 221-6	5.5	177
39	4-Bromo-2,5-dimethoxyphenethylamine (2C-B): presence in the recreational drug market in Spain, pattern of use and subjective effects. <i>Journal of Psychopharmacology</i> , 2012 , 26, 1026-35	4.6	74
38	Surviving life-threatening MDMA (3,4-methylenedioxymethamphetamine, ecstasy) toxicity caused by ritonavir (RTV). <i>Intensive Care Medicine</i> , 2012 , 38, 1239-40	14.5	12
37	Acute effects of a single, oral dose of d9-tetrahydrocannabinol (THC) and cannabidiol (CBD) administration in healthy volunteers. <i>Current Pharmaceutical Design</i> , 2012 , 18, 4966-79	3.3	165
36	Changes in CYP1A2 activity in humans after 3,4-methylenedioxymethamphetamine (MDMA, ecstasy) administration using caffeine as a probe drug. <i>Drug Metabolism and Pharmacokinetics</i> , 2012 , 27, 605-13	2.2	18
35	Sex differences in 3,4-methylenedioxymethamphetamine (MDMA; ecstasy)-induced cytochrome P450 2D6 inhibition in humans. <i>Clinical Pharmacokinetics</i> , 2011 , 50, 319-29	6.2	24
34	Author response to the Letter to the Editor of Tfelt-Hansen. <i>European Journal of Clinical Pharmacology</i> , 2011 , 67, 645-646	2.8	
33	Antioxidant activities of hydroxytyrosol main metabolites do not contribute to beneficial health effects after olive oil ingestion. <i>Drug Metabolism and Disposition</i> , 2010 , 38, 1417-21	4	50
32	Neurotoxic thioether adducts of 3,4-methylenedioxymethamphetamine identified in human urine after ecstasy ingestion. <i>Drug Metabolism and Disposition</i> , 2009 , 37, 1448-55	4	27
31	Study of paracetamol 1-g oral solution bioavailability. <i>Methods and Findings in Experimental and Clinical Pharmacology</i> , 2008 , 30, 37-41		5
30	MDMA-assisted psychotherapy using low doses in a small sample of women with chronic posttraumatic stress disorder. <i>Journal of Psychoactive Drugs</i> , 2008 , 40, 225-36	3.6	90
29	The consequences of 3,4-methylenedioxymethamphetamine induced CYP2D6 inhibition in humans. <i>Journal of Clinical Psychopharmacology</i> , 2008 , 28, 523-9	1.7	42
28	Pharmacological interaction between 3,4-methylenedioxymethamphetamine (ecstasy) and paroxetine: pharmacological effects and pharmacokinetics. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2007 , 323, 954-62	4.7	84
27	Implications of mechanism-based inhibition of CYP2D6 for the pharmacokinetics and toxicity of MDMA. <i>Journal of Psychopharmacology</i> , 2006 , 20, 842-9	4.6	74
26	Efficacy of antidepressants in substance use disorders with and without comorbid depression. A systematic review and meta-analysis. <i>Drug and Alcohol Dependence</i> , 2005 , 78, 1-22	4.9	196
25	Contribution of cytochrome P450 2D6 to 3,4-methylenedioxymethamphetamine disposition in humans: use of paroxetine as a metabolic inhibitor probe. <i>Clinical Pharmacokinetics</i> , 2005 , 44, 649-60	6.2	53
24	MDMA (ecstasy) pharmacokinetics in a CYP2D6 poor metaboliser and in nine CYP2D6 extensive metabolisers. <i>European Journal of Clinical Pharmacology</i> , 2005 , 61, 551-4	2.8	42

(1996-2004)

23	Repeated doses administration of MDMA in humans: pharmacological effects and pharmacokinetics. <i>Psychopharmacology</i> , 2004 , 173, 364-75	4.7	102
22	Putting clinical pharmacology in context: the use of popular movies. <i>Journal of Clinical Pharmacology</i> , 2004 , 44, 30-6	2.9	22
21	Human pharmacology of MDMA: pharmacokinetics, metabolism, and disposition. <i>Therapeutic Drug Monitoring</i> , 2004 , 26, 137-44	3.2	324
20	Hydroxytyrosol disposition in humans. <i>Clinical Chemistry</i> , 2003 , 49, 945-52	5.5	241
19	Determination of MDMA and its metabolites in blood and urine by gas chromatography-mass spectrometry and analysis of enantiomers by capillary electrophoresis. <i>Journal of Analytical Toxicology</i> , 2002 , 26, 157-65	2.9	88
18	3,4-Methylenedioxymethamphetamine (ecstasy) and alcohol interactions in humans: psychomotor performance, subjective effects, and pharmacokinetics. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2002 , 300, 236-44	4.7	125
17	On-site testing of 3,4-methylenedioxymethamphetamine (ecstasy) in saliva with Drugwipe and Drugread: a controlled study in recreational users. <i>Clinical Chemistry</i> , 2002 , 48, 174-6	5.5	5
16	Prevalence and risk of gingival enlargement in patients treated with nifedipine. <i>Journal of Periodontology</i> , 2001 , 72, 605-11	4.6	57
15	Usefulness of saliva for measurement of 3,4-methylenedioxymethamphetamine and its metabolites: correlation with plasma drug concentrations and effect of salivary pH. <i>Clinical Chemistry</i> , 2001 , 47, 1788-95	5.5	19
14	Non-linear pharmacokinetics of MDMA ('ecstasy') in humans. <i>British Journal of Clinical Pharmacology</i> , 2000 , 49, 104-9	3.8	247
13	Pharmacology of MDMA in humans. Annals of the New York Academy of Sciences, 2000, 914, 225-37	6.5	115
12	Human pharmacology of 3,4-methylenedioxymethamphetamine ("ecstasy"): psychomotor performance and subjective effects. <i>Journal of Clinical Psychopharmacology</i> , 2000 , 20, 455-66	1.7	156
11	Cardiovascular and neuroendocrine effects and pharmacokinetics of 3, 4-methylenedioxymethamphetamine in humans. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 1999 , 290, 136-45	4.7	197
10	Abuse liability of flunitrazepam among methadone-maintained patients. <i>Psychopharmacology</i> , 1998 , 140, 486-95	4.7	34
9	Tolerability and pharmacokinetics of ebrotidine in healthy subjects given single and repeated oral doses. <i>Arzneimittelforschung</i> , 1997 , 47, 528-30		
8	Cocaine and alcohol interactions in humans: neuroendocrine effects and cocaethylene metabolism. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 1997 , 283, 164-76	4.7	88
7	Clinical pharmacokinetics and tolerability of dotarizine in healthy subjects after single and multiple oral administration. <i>Methods and Findings in Experimental and Clinical Pharmacology</i> , 1997 , 19, 343-50		
6	Gingival enlargement induced by drugs. <i>Drug Safety</i> , 1996 , 15, 219-31	5.1	50

5	A comparison of the acute behavioral effects of flunitrazepam and triazolam in healthy volunteers. <i>Psychopharmacology</i> , 1996 , 125, 1-12	4.7	23
4	Cross-reactivity of stimulants found in sports drug testing by two fluorescence polarization immunoassays. <i>Journal of Analytical Toxicology</i> , 1996 , 20, 165-70	2.9	18
3	Sensation seeking amongst healthy volunteers participating in phase I clinical trials. <i>British Journal of Clinical Pharmacology</i> , 1995 , 39, 405-9	3.8	14
2	Spanish version of the 49-item short form of the Addiction Research Center Inventory (ARCI). <i>Drug and Alcohol Dependence</i> , 1994 , 35, 203-9	4.9	38
1	Alcohol and cocaine interactions in humans. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 1993 , 266, 1364-73	4.7	134